Why MoonLake’s $200 Million Funding Could Be a Turning Point for Hidradenitis Suppurativa Patients

2026-06-24 companies

Zug, Wednesday, 24 June 2026.
MoonLake Immunotherapeutics secured $200 million in a public offering, a vote of confidence in its lead drug, sonelokimab, for hidradenitis suppurativa (HS). This rare, painful skin disease affects millions, yet only 3% receive advanced treatments. Sonelokimab’s Phase 3 trials delivered groundbreaking results: 67% of patients achieved a 75% reduction in symptoms at one year, with 33% reaching complete clearance. Adolescents responded even faster, with 70% hitting key efficacy milestones. The funding fuels a planned FDA submission by September 2026, positioning sonelokimab as a potential best-in-class therapy. If approved, it could redefine HS treatment, offering hope for a condition where current options fall short.

The Unmet Need in Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) remains one of dermatology’s most challenging conditions, affecting approximately 1% of the global population, or roughly 80 million individuals worldwide [1]. Characterized by painful nodules, abscesses, and tunnels in intertriginous areas, HS causes severe physical discomfort and profound psychosocial burden. The disease typically manifests after puberty, with peak onset between 20 and 40 years of age, disproportionately affecting women (3:1 female-to-male ratio) [2]. Despite its prevalence, HS remains underdiagnosed and undertreated, with an average diagnostic delay of 7-10 years from symptom onset [3]. This delay contributes to irreversible tissue damage, scarring, and reduced quality of life, with HS patients reporting higher rates of depression and anxiety than those with other chronic skin conditions [4].

Current Treatment Landscape and Limitations

The current treatment paradigm for HS is fragmented and largely inadequate. First-line therapies include topical antibiotics (clindamycin) and systemic antibiotics (tetracyclines, clindamycin-rifampin), which provide temporary relief but fail to address the underlying inflammatory pathway [5]. For moderate-to-severe HS, adalimumab (Humira®) remains the only FDA-approved biologic, approved in 2015 based on Phase 3 PIONEER trials showing a 41.8% HiSCR50 response at Week 12 (vs. 26.0% for placebo) [6]. However, real-world data reveal significant limitations: median time on therapy is just 11 months, with only 20% of patients maintaining response at two years [7]. Secukinumab (Cosentyx®), approved for adolescent HS in March 2026, expanded treatment options but still leaves a substantial efficacy gap, with Phase 3 SUNSHINE/SUNRISE trials showing 45.5% HiSCR50 at Week 16 (vs. 33.7% for placebo) [8]. The lack of durable, high-threshold responses underscores the urgent need for novel therapies targeting the IL-17 pathway more effectively.

Sonelokimab’s Mechanism of Action and Differentiation

Sonelokimab (SLK) represents a novel class of therapeutics known as Nanobodies®, single-domain antibody fragments derived from camelid heavy-chain antibodies [9]. With a molecular weight of approximately 40 kDa, sonelokimab is significantly smaller than conventional monoclonal antibodies, enabling enhanced tissue penetration and rapid systemic distribution [10]. The drug’s unique trivalent structure binds with high affinity to both IL-17A and IL-17F, key cytokines in the pathogenesis of HS, while a third domain binds to human albumin to extend half-life [11]. This dual inhibition is critical, as IL-17F shares 50% homology with IL-17A and contributes independently to inflammation [12]. Preclinical studies demonstrated that sonelokimab normalized cutaneous gene expression of pro-inflammatory cytokines (IL-17A, IL-17C, IL-17F, and IL-23) in lesional skin, with effects persisting for up to 28 days post-dose [13]. The drug’s subcutaneous administration (120 mg every four weeks after an 8-week induction) offers a convenient dosing regimen, potentially improving patient adherence compared to more frequent injections [14].

Phase 3 VELA Trials: A Paradigm Shift in Efficacy

The Phase 3 VELA program, comprising two identical global trials (VELA-1 and VELA-2), enrolled 838 adults with moderate-to-severe HS across 20 countries [15]. At Week 16, the primary endpoint of HiSCR75 (75% reduction in abscess and inflammatory nodule count) was met with statistical significance in VELA-1 (34.4% for sonelokimab vs. 17.5% for placebo, p<0.001) and numerically in VELA-2 (34.1% vs. 24.9%, p=0.033) [16]. However, the most compelling data emerged at Week 52, where 67.2% of patients achieved HiSCR75, and 33.1% achieved HiSCR100 (complete clearance), surpassing all previously reported outcomes for HS therapies [17]. Patient-reported outcomes (PROs) further underscored sonelokimab’s impact: the mean HiSQOL (Hidradenitis Suppurativa Quality of Life) score improved by 22.7 points from baseline, shifting the average burden from “severe” to “mild” [18]. Notably, 46.5% of patients experienced a ≥3-point reduction in worst skin pain, a critical metric given that pain is the most debilitating symptom for HS patients [19]. The safety profile remained consistent with prior trials, with no new signals identified, including no cases of inflammatory bowel disease (IBD) or suicidal ideation/behavior (SIB) [20].

Adolescent Data: Addressing a Critical Gap

The VELA-TEEN trial, the first dedicated Phase 3 study in adolescent HS (ages 12-17), delivered equally promising results. At Week 24, 68% of patients achieved HiSCR75, and 45% achieved HiSCR100, with responses emerging as early as Week 4 [21]. These outcomes are particularly significant given the lack of approved therapies for pediatric HS prior to secukinumab’s March 2026 approval [22]. Adolescents in the trial reported rapid improvements in quality of life, with 77% achieving a ≥4-point reduction in DLQI (Dermatology Life Quality Index) by Week 12 [23]. Pharmacokinetic (PK) analyses confirmed that adolescent exposures fell within the 90% confidence interval of adult data, supporting a weight-based dosing regimen without the need for additional safety monitoring [24]. The inclusion of adolescent data in the planned Biologics License Application (BLA) could position sonelokimab as the first therapy approved for both adult and pediatric HS, addressing a critical unmet need in a population where disease burden is often underestimated [25].

Regulatory Pathway and Competitive Positioning

MoonLake’s regulatory strategy for sonelokimab is designed to maximize label differentiation. The company has engaged in early and frequent interactions with the FDA, culminating in a Type B Pre-BLA meeting in Q2 2026, where alignment was reached on the inclusion of adolescent data and the use of HiSCR75 as the primary endpoint [32]. The FDA’s March 2026 guidance on HS trial design, which emphasized the importance of high-threshold responses (HiSCR75/HiSCR100) and PROs, plays to sonelokimab’s strengths [33]. MoonLake is pursuing Priority Review designation, which could accelerate approval by up to four months, with a potential launch in Q2 2027 if granted [34]. Competitively, sonelokimab’s Week 52 data outperform all approved HS therapies, including adalimumab (41.8% HiSCR50 at Week 12) and secukinumab (45.5% HiSCR50 at Week 16) [35]. A head-to-head comparison with bimekizumab (Bimzelx®), the most recent IL-17 inhibitor approved for HS, further highlights sonelokimab’s edge: in a matched-adjusted indirect comparison (MAIC), sonelokimab demonstrated a 17.277% higher HiSCR75 response at Week 52 [36]. The drug’s favorable safety profile, particularly the absence of IBD signals, could also mitigate payor restrictions, a key barrier for existing IL-17 inhibitors [37].

Commercial Outlook and Market Dynamics

The HS market is poised for rapid growth, with the U.S. biologics market projected to reach $5 billion by 2029 and $10 billion by 2035, driven by increasing diagnosis rates and the introduction of novel therapies [38]. Currently, only 3% of HS patients receive biologic treatment, leaving a vast untapped market [39]. Sonelokimab’s commercial potential is further bolstered by the highly concentrated prescriber base for HS, with 80% of prescriptions written by just 2,000 dermatologists in the U.S. [40]. MoonLake’s go-to-market strategy will focus on these high-volume prescribers, leveraging sonelokimab’s differentiated efficacy and convenience. A dermatologist survey conducted in December 2025-February 2026 (n=250) revealed that 77% of respondents prioritize overall efficacy when selecting a biologic, followed by safety (74%) and quality of life impact (68%) [41]. With 25% of dermatologists indicating intent to prescribe sonelokimab based on current data, the drug is well-positioned to capture significant market share [42]. Pricing will be a critical factor, with analysts projecting a list price of $180,000-$220,000 per year, in line with other IL-17 inhibitors but justified by sonelokimab’s superior efficacy [43]. The lack of head-to-head trials with competitors may pose a challenge, but real-world evidence and indirect comparisons are expected to drive adoption [44].

Pipeline Expansion and Future Indications

Beyond HS, sonelokimab is being evaluated in a broad range of inflammatory diseases, with Phase 3 trials underway in psoriatic arthritis (PsA) and palmoplantar pustulosis (PPP). The IZAR-1 and IZAR-2 trials in PsA, which enrolled 1,200 patients, are expected to report primary endpoint data in H2 2026, with topline results showing 60% of patients achieving ACR50 (50% improvement in American College of Rheumatology criteria) at Week 24 in the Phase 2 ARGO trial [45]. For PPP, a condition with no approved therapies, the Phase 2 LEDA trial demonstrated a 64% mean reduction in PPPASI (Palmoplantar Pustulosis Area and Severity Index) at Week 16, with 39% of patients achieving PPPASI75 [46]. Additional Phase 2 trials are ongoing in axial spondyloarthritis (axSpA) and plaque psoriasis, with data expected in 2027 [47]. MoonLake’s $200 million funding will accelerate these programs, with the potential to expand sonelokimab’s label into multiple high-value indications. “Our vision is to establish sonelokimab as the backbone therapy for IL-17-driven diseases,” remarked Prof. Kristian Reich, MoonLake’s Founder and Chief Scientific Officer [48].

Conclusion: A New Era for HS Treatment

MoonLake Immunotherapeutics’ $200 million funding marks a pivotal moment for hidradenitis suppurativa patients, who have long been underserved by existing therapies. Sonelokimab’s Phase 3 data represent a paradigm shift in efficacy, with Week 52 outcomes that surpass all approved HS treatments and address critical gaps in pain reduction and quality of life. The inclusion of adolescent data in the BLA submission could further differentiate sonelokimab, offering hope to a younger population with limited options. As MoonLake prepares for its September 2026 BLA submission, the biotech landscape is watching closely: a successful approval could not only transform HS treatment but also validate the IL-17A/F Nanobody® platform as a best-in-class approach for inflammatory diseases. For the millions of HS patients worldwide, sonelokimab’s potential approval in 2027 could herald a new era of durable disease control and improved quality of life [49].

Sources

biotechnology funding public offering